Lance Daniel Laird

Dr. Lance Daniel Laird

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
LLLance Daniel Laird
Lance Daniel Laird
MAM. M Amer
M. M Amer
EBE. D Barnett
E. D Barnett
LBLinda L. Barnes
Linda L. Barnes
This article provides a framework for understanding how Muslim identity, and the current social and political contexts in which it is shaped, affects the health of Muslims in the UK and the US, and the quality of health care they receive. Key medical and public health literature that addresses health concerns related to Muslim communities in the UK and the US is reviewed. Few data exist specific to health disparities for Muslim minorities. However, the article focuses on emerging studies concerning the consequences of "Islamophobia" for the physical and mental health and health care of Muslim families and children. We argue that, despite substantive structural differences in the health care systems of the UK and the US, social structural and political forces play similar roles in the health of Muslim children in both countries. Finally, we call for significant cultural and institutional adjustments in health care settings and further research studies to provide specific data to address health disparities for these growing and diverse populations.

10 May 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SMSuzanne E Mitchell
Suzanne E Mitchell
ABAlexa Bragg
Alexa Bragg
BCBarbara A De La Cruz
Barbara A De La Cruz
MWMichael R Winter
Michael R Winter
MRMatthew J Reichert
Matthew J Reichert
PGPaula Gardiner
Paula Gardiner
Background: Medically underserved people with type 2 diabetes mellitus face limited access to group-based diabetes care, placing them at risk for poor disease control and complications. Immersive technology and telemedicine solutions could bridge this gap. Objective: The purpose of this study was to compare the effectiveness of diabetes medical group visits (DMGVs) delivered in an immersive telemedicine platform versus an in-person (IP) setting and establish the noninferiority of the technology-enabled approach for changes in hemoglobin A1c (HbA1c) and physical activity (measured in metabolic equivalent of task [MET]) at 6 months. Methods: This study is a noninferiority randomized controlled trial conducted from February 2017 to December 2019 at an urban safety net health system and community health center. We enrolled adult women (aged ≥18 years) who self-reported African American or Black race or Hispanic or Latina ethnicity and had type 2 diabetes mellitus and HbA1c ≥8%. Participants attended 8 weekly DMGVs, which included diabetes self-management education, peer support, and clinician counseling using a culturally adapted curriculum in English or Spanish. In-person participants convened in clinical settings, while virtual world (VW) participants met remotely via an avatar-driven, 3D VW linked to video teleconferencing. Follow-up occurred 6 months post enrollment. Primary outcomes were mean changes in HbA1c and physical activity at 6 months, with noninferiority margins of 0.7% and 12 MET-hours, respectively. Secondary outcomes included changes in diabetes distress and depressive symptoms. Results: Of 309 female participants (mean age 55, SD 10.6 years; n=195, 63% African American or Black; n=105, 34% Hispanic or Latina; n=151 IP; and n=158 in VW), 207 (67%) met per-protocol criteria. In the intention-to-treat analysis, we confirmed noninferiority for primary outcomes. We found similar improvements in mean HbA1c by group at 6 months (IP: –0.8%, SD 1.9%; VW: –0.5%, SD 1.8%; mean difference 0.3, 97.5% CI –∞ to 0.3; P<.001). However, there were no detectable improvements in physical activity (IP: –6.5, SD 43.6; VW: –9.6, SD 44.8 MET-hours; mean difference –3.1, 97.5% CI –6.9 to ∞; P=.02). The proportion of participants with significant diabetes distress and depressive symptoms at 6 months decreased in both groups. Conclusions: In this noninferiority randomized controlled trial, immersive telemedicine was a noninferior platform for delivering diabetes care, eliciting comparable glycemic control improvement, and enhancing patient engagement, compared to IP DMGVs. Trial Registration: ClinicalTrials.gov NCT02726425; https://clinicaltrials.gov/ct2/show/NCT02726425


1 December 2007 in Social Science & Medicine
Verified
Journal Article
Closed access
LLLance Daniel Laird
Lance Daniel Laird
JMJustine de Marrais
Justine de Marrais
LBLinda L. Barnes
Linda L. Barnes

1 April 2022 in Patient Education and Counseling
Verified
Journal Article
Closed access
SMSuzanne Mitchell
Suzanne Mitchell
ABAlexa Bragg
Alexa Bragg
PGPaula Gardiner
Paula Gardiner
BCBarbara De La Cruz
Barbara De La Cruz
LLLance Daniel Laird
Lance Daniel Laird

1 March 2017 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
PGPaula Gardiner
Paula Gardiner
ALAnna Sophia Lestoquoy
Anna Sophia Lestoquoy
KGKatherine Gergen-Barnett
Katherine Gergen-Barnett
BPBrian Penti
Brian Penti
LWLaura F White
Laura F White
JLJane M. Liebschutz
Jane M. Liebschutz